. Author manuscript; available in PMC: 2017 Nov 15.

Published in final edited form as: Cancer. 2016 Aug 10;122(21):3336–3343. doi: 10.1002/cncr.30197

Table 2.

Treatment response among the matched patients with CML-CP treated with dasatinib and nilotinib.

	No. (%)		P value
	Dasatinib (N = 87)	Nilotinib (N = 87)	P value
Response at 3 months
BCR/ABL1 <10%	81 (93)	82 (94)	0.25
Cumulative response at 12 months
MR^4.0	42 (48)	44 (51)	0.88
MR^4.5	31 (36)	37 (43)	0.34
MMR	67 (77)	74 (85)	0.13
CCyR	82 (94)	82 (94)	0.51
Cumulative response at 36 months
MR^4.0	60 (69)	62 (71)	0.73
MR^4.5	57 (66)	56 (64)	0.96
MMR	77 (89)	80 (92)	0.17
CCyR	82 (94)	82 (94)	0.51

NOTE: CCyR: Complete cytogenetic response, MMR: Major molecular response (BCR-ABL1/ABL1 ratio ≤ 0.1% by international scale [IS]), MR^4.0: Molecular response with 4 log reduction (BCR-ABL1/ABL1 ratio ≤ 0.01% by IS), MR^4.5: Molecular response with 4.5 log reduction (BCR-ABL1/ABL1 ratio ≤ 0.0032% by IS)